Xynomic Pharmaceuticals

Xynomic Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of oncology therapies. The company's lead program is abexinostat, a novel histone deacetylase (HDAC) inhibitor being evaluated in pivotal trials for renal cell carcinoma and various lymphomas. Xynomic's pipeline also includes small molecule inhibitors targeting focal adhesion kinase (FAK) and RAF kinase, acquired through partnerships with major pharmaceutical companies like Boehringer Ingelheim. The company operates with a global footprint, maintaining significant R&D and clinical operations in both the United States and China. Xynomic aims to address unmet medical needs in cancer treatment through the strategic in-licensing and development of high-potential drug candidates.